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THE SURFACE ULTRASTRUCTURE
OF EXFOLIATED CERVICAL CELLS.
A. E. WILLIAMS, Teaching and Research
Centre, Western General Hospital, Edinburgh
and J. F. MURPHY, J. M. ALLEN and J. A.
JORDAN. Department of Obstetrics and
Gynaecology, University of Birmingham.
We have previously (Murphy et al.,
SEM/1ITRI. 1973, p. 605 and Br. J. Cancer,
1973, 28, 86) studied exfoliated cervical cells
by scanning electron microscopy (SEM).
Recently critical point drying has been
introduced and it has become possible to
stain cells before SEM study, thus making
identification easier.
Cell samples were prepared (1) by scraping
from the cervix, staining and processing for
SEM study and (2) by removing cells from
colposcopically directed areas on the cervix
with a membrane filter. A total of 138
patients were studied and characteristic
differences were noted between the surface
ultrastructure of benign and malignant cells.
Dyskariotic cells showed a mixture of surface
types between normal and frankly abnormal.
Differences were observed in the SEM
between cells that appeared identical by light
microscopy. In particular, a tendency to
surface abnormality existed on cells that
were normal by light microscopy when the
cells were adjacent to abnormal cells.
MEASUREMENT OF CARCINO-
EMBRYONIC ANTIGEN (CEA) IN
NORMAL SUBJECTS AND IN
VARIOUS NEOPLASTIC AND NON-
NEOPLASTIC DISORDERS. P. FRANCHI-
MONT, P. F. ZANGERLE, M. L. DEBRUCHE,
P. CONINX and J. PROYARD. Institut de
Medecine, University of Liege, Belgium.
A method of assay of CEA not requiring
prior extraction has been described. Various
essential criteria foravalidradioimmunoassay
have been fulfilled; the use of a preparation
of labelled CEA reasonably freed of contami-
nants and of molecules damaged by the
labelling reaction, acquisition of specific
antibodies, use of an efficient system of
separation of free labelled CEA from that
bound to antibody (the double antibody
technique) and application of the assay
method to biological fluids, in particular,
serum. The sensitivity ofthis method allows
the detection of 0 5-1 ng/ml of serum; the
precision and the reproducibility of the
results are very satisfactory.
CEA could be detected in the serum of
only 4.2% of 1017 normal subjects. The sera
of 205 patients suffering from a neoplasm
formally diagnosed were investigated: CEA
was found in the sera of 145, i.e. 70 7%.
Among these patients 24 were investigated
before any treatment: 21 had detectable
CEA concentrations (i.e. 87%). Of 54
patients with metastases 48 (i.e. 89%) had
detectable levels of CEA. The levels were
especially high when metastases were present:
61% ofthese patients had values greater than
10 ng/ml. The levels of CEA were also
measured in the sera of 43 patients during
treatment with cytostatic drugs. In the
non-neoplastic gastrointestinal disorders,
CEA was found in 29% of the sera and in
non-neoplastic lung disorders, 15.3% had
detectable CEA levels the values of which
were usually lower than 10 ng/ml. The assay
for CEA appears to be a useful method in the
diagnosis of cancerous diseases and the
follow-up of treatments in carcinoma.
CLINICAL EVALUATION OF CEA
IN URINE OF PATIENTS WITH
BLADDER CARCINOMA. C. B. KORSTEN,
J-P. PERSIJN and J. RENAUD. Netherlands
Cancer Institute, Amsterdam.
Urine from 73 patients was analysed for
CEA (carcinoembryonic antigen) using a
radioimmunoassay. The findings in 66
patients are summarized in the Table.
Incidence of urinary
CEA 30 ng/ml
Previous
radio- Without With
therapeutic urinary urinary
treatment State of disease infection infection
None No evidence of 0/11 5/5
bladder cancer
None Evidence of 8/8 4/4
bladder cancer
Yes No evidence of 2/21 3/3
recurrence of
the disease
Yes No evidence of 9/10 4/4
regression during
follow-up
In another group of 7 patients without
evidence of urinary infection CEA was
determined before and after therapy. In 5